Impact of the initial administration of an antiretroviral drug with latency reversal properties on the HIV reservoir size
Erick De La Torre Tarazona(Instituto de Salud Carlos III), Vicente Boix, Luz Balsalobre(Santa Lucía University General Hospital), Esperanza Merino(Universitat de Miguel Hernández d'Elx), Rafael Rubio(Research Institute Hospital 12 de Octubre), Mercedes García‐Gasalla(Health Research Institute of the Balearic Islands), Félix Ortega Gutiérrez(International Olive Council), Teresa Gómez‐García(The Coordinating Center), Iván Agea, Francesc Vidal(Institut de Recerca Biomèdica Catalunya Sud), Féderico García, Elisa Moraga(Hospital Clínic de Barcelona), Laura Luna(Instituto de Salud Carlos III), Juan Berenguer(Instituto de Salud Carlos III), Inmaculada Jarrín(Instituto de Salud Carlos III), Sergio Reus(Instituto de Salud Carlos III), José Sánchez–Payá(Biogipuzkoa Health Research Institute), Luís F. López‐Cortés(Instituto de Salud Carlos III), Livia Giner, Joaquín Portilla(Hospital General Universitario de Alicante Doctor Balmis), Eva Poveda(Madrid Health Service), Sergio Serrano‐Villar, José Alcamı́(Apple (Israel)), Irene Portilla, María Ángeles Muñoz‐Fernández(Instituto de Salud Carlos III), Marta Rava(Instituto de Salud Carlos III), Gema García-Sáez(Hospital de Basurto), Roxana Juárez, Cristina Moreno(Hospital General Universitario Gregorio Marañón), Lucio García‐Fraile(Instituto de Salud Carlos III), Maria Gonzalez, Juan Carlos Rodrı́guez(Hospital General Universitario de Alicante Doctor Balmis), Santiago Moreno(Universidad El Bosque), David Dalmau(University Hospital Mútua de Terrassa), Elisa de Lazzari(Hospital Clínic de Barcelona), Ma Luisa Masó Navarro, José Antonio Iribarren(Biogipuzkoa Health Research Institute), Juan González, Joaquim Peraire(Instituto de Salud Carlos III), Sonsoles Sánchez-Palomino(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Raúl Vaquer(Instituto Ramón y Cajal de Investigación Sanitaria), Cristina Marco, Sònia Vicens-Artés(Hospital Clínic de Barcelona), Rebeca Izquierdo
Cited by 5
Related Papers
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths
|Science Immunology|2021|638
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies
|The Lancet HIV|2023|506
Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV–HCV International Panel
|AIDS|2002|443
Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain
|Clinical Microbiology and Infection|2020|423
Description of COVID-19 in HIV-infected individuals: a single-centre, prospective cohort
|The Lancet HIV|2020|396